Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Work In Process (2016 - 2020)

United Therapeutics' Work In Process history spans 11 years, with the latest figure at $28.1 million for Q1 2020.

  • On a quarterly basis, Work In Process rose 6.84% to $28.1 million in Q1 2020 year-over-year; TTM through Mar 2020 was $28.1 million, a 6.84% increase, with the full-year FY2019 number at $29.1 million, up 3.93% from a year prior.
  • Work In Process hit $28.1 million in Q1 2020 for United Therapeutics, down from $29.1 million in the prior quarter.
  • Over the last five years, Work In Process for UTHR hit a ceiling of $29.8 million in Q3 2019 and a floor of $22.9 million in Q1 2017.
  • Historically, Work In Process has averaged $26.2 million across 5 years, with a median of $26.2 million in 2016.
  • Biggest five-year swings in Work In Process: grew 21.29% in 2016 and later dropped 13.33% in 2017.
  • Tracing UTHR's Work In Process over 5 years: stood at $24.9 million in 2016, then decreased by 3.21% to $24.1 million in 2017, then grew by 16.18% to $28.0 million in 2018, then grew by 3.93% to $29.1 million in 2019, then fell by 3.44% to $28.1 million in 2020.
  • Business Quant data shows Work In Process for UTHR at $28.1 million in Q1 2020, $29.1 million in Q4 2019, and $29.8 million in Q3 2019.